A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells and hUCMSCs and hCBMNCs in Premature Ovarian Failure,, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2012-12-05.
Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Primary Ovarian Insufficiency with a site in China — 14 open to participants now, 16 under way, none of them phase 3. Primary Ovarian Insufficiency · China.
Among the 40 studies in Primary Ovarian Insufficiency with a site in China, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 1/2, and was the 1st registered.
181 studies on the registry are indexed under Primary Ovarian Insufficiency; 48 are open to participants now.
Browse Primary Ovarian Insufficiency studies →14 of the 40 studies in Primary Ovarian Insufficiency with a site in China are open now. Recruiting first, the newest first:
Shenzhen Wingor Biotechnology Co., Ltd. · Sites in China
Ages 18–40 · Women only
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18–50 · Women only
Yan Hongli · Sites in China
Ages 20–40 · Women only
Rui Yang · Sites in China
Ages 20–39 · Women only
Shi Yun · Sites in China
Ages 18–39 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Primary Ovarian Insufficiency studies recruiting now, 1 (4%) sets no upper age limit and 24 (89%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 39 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 4 2
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 48 across 113 interventional studies indexed under Primary Ovarian Insufficiency.
Median enrollment 50 across the 27 interventional studies, 260 across the 13 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
Shenzhen Beike Bio-Technology Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Shenzhen Beike Bio-Technology Co., Ltd. has 1 study filed under Primary Ovarian Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Primary Ovarian Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07843030Shi YunEffect and Mechanism of Jiajian Guishen Optimized Formula on Premature Ovarian Insufficiency: Insights Into m6A Modification and Oxidative Stress | 2026-12-30 |
| NCT06481969Rui YangApplication of Autologous Adipose Stromal Vascular Fraction in the Treatment of Premature Ovarian Insufficiency | 2026-12-30 |
| NCT06067529Women's Hospital School Of Medicine Zhejiang UniversityA Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency | 2026-12-31 |
| NCT06645379The Fourth Affiliated Hospital of Zhejiang University School of MedicineApplication of Platelet-rich Plasma (PRP) in Reproductive Medicine | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Primary Ovarian Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important physical and psychological consequences/impact in those patients.
Premature ovarian failure (POF) is currently managed by non-physiological sex steroid regimens which are inadequate at optimizing uterine characteristics.
Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for POF.
In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure. Participants will be followed for an expected average of 48 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
Biological: human umbilical cord mesenchymal stem cells
Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
Biological: hUCMSCs and hCBMNCs
Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
Biological: human cord blood mononuclear cells
Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
Drug: Hormone Replacement Therapy
Serum Level of follicle-stimulating hormone
Time frame: 48 weeks after treatment
Uterine and Ovary characteristics of B ultrasound, including Uterine/Ovarian size and Blood Flow
Time frame: 48 weeks after treatment
Modified Kupperman Score
Time frame: 48 weeks after treatment
Incidence of Adverse Events and Serious Adverse Events
Time frame: 48 weeks after treatment
The record gives a start of Mar 2012, a primary completion of Jun 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel
Primary Ovarian Insufficiency →
Shenzhen Beike Bio-Technology Co., Ltd.